Two non‐selective FGFR1–3 inhibitors, erdafitinib (JNJ‐42756493) and pemigatinib (INCB054828) have been approved and are being marketed to treat bladder cancer and cholangiocarcinoma in patients with FGFR2 or FGFR3 rearrangements.10, 11. The gene discussed is FGFR1; the disease is urinary bladder carcinoma.